Human Milk Fortifier - Grwoth Evaluation

This study has been completed.
Information provided by (Responsible Party):
Nestlé Identifier:
First received: January 8, 2013
Last updated: April 7, 2015
Last verified: January 2015
It it is hypothesized that the growth of preterm infants receiving a new human milk fortifier will be equal or superior to the growth of preterm infants receiving a currently marketed human milk fortifier with a lower protein content.

Condition Intervention
Premature Birth
Dietary Supplement: Human milk fortifier

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Supportive Care
Official Title: Evaluation of Growth of Pre-Term Infants Fed a Human Milk Fortifier

Further study details as provided by Nestlé:

Primary Outcome Measures:
  • Weight gain (g/d) between full strength fortification with full volume intake (day 1) through 21 days of study after that day. [ Time Frame: 21 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 240
Study Start Date: April 2011
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: New human milk fortifier
New human milk fortifier
Dietary Supplement: Human milk fortifier
Active Comparator: Currently marketed fortifier
Currently marketed fortifier
Dietary Supplement: Human milk fortifier


Ages Eligible for Study:   up to 1 Month
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Birth weight ≤1500 g AND/OR gestational age ≤32 weeks (determined by maternal dates, fetal ultrasound, Dubowitz/Ballard examination or a combination thereof)
  • Male or female
  • Tolerating an enteral intake of human milk, donor milk or a combination at ≥100 mL/kg/d for ≥ 24 h
  • Subject is anticipated to receive human milk, donor milk or a combination for ≥ 3 consecutive weeks after having achieved full fortification with volume intake contained between 150 and 180 mL/kg/d.
  • Written informed consent has been obtained from the legal representative(s).

Exclusion Criteria:

  • Infants with current systemic disease
  • Infants with a history of systemic disease
  • Any congenital anomalies of the GI tract that significantly interfere with nutrition and growth or previous GI surgery.
  • Small size for gestational age (SGA) - body weight ≦ 5th percentile for that gestational age.
  • Infants diagnosed with any inherent metabolic disease.
  • Infants diagnosed with any chromosomic disease.
  • Receiving any commercial formula supplementation to breast milk.
  • Receiving steroids at the time of enrollment.
  • Participation in another nutritional clinical trial that may affect outcomes of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01771588

CHR de la Citadelle
Liège, Belgium, 4000
Hôpital des Enfants - CHU Pellegrin
Bordeaux, France, 33000
CHU Caen
Caen, France, 14033
CHU Grenoble
Grenoble, France, 38043
Hôpital de la Croix-Rousse
Lyon, France, 69317
Hôpital de la Conception Marseille
Marseille, France, 13005
Maternité Régionale
Nancy, France, 54042
Hôpital Clocheville Tours
Tours, France, 37000
Klinikum Ernest von Bergmann
Potsdam, Germany, 14467
Policlinico Mangiagalli e Regina Elena
Milano, Italy, 20122
Luzern, Switzerland, 6000
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Nestlé Identifier: NCT01771588     History of Changes
Other Study ID Numbers: 08.08.INF 
Study First Received: January 8, 2013
Last Updated: April 7, 2015
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor Complications
Obstetric Labor, Premature
Pregnancy Complications processed this record on February 11, 2016